Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2002-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included

• Body Mass Index (BMI) maximum 35 kg/m^2

• Fasting plasma glucose 7-15 mmol/l, both inclusive

Exclusion Criteria:

• Impaired liver function

• Impaired renal function

• Anaemia

• Cardiac disease

• Uncontrolled treated/untreated hypertension

• Recurrent major hypoglycaemia as judged by the Investigator

• Known or suspected allergy to trial product or related products

• Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures

• Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness

• Loss of more than 400 ml blood during the three months prior to study start

• Allergy to paracetamol